S everal biological properties of glutamine (G) make this nonessential amino acid a good candidate for nutritional intervention in critical illness: It is an important energy substrate for immune cells (1) and for the intestinal epithelium (2). Besides being a major nitrogen carrier from muscle tissues to the digestive tract and the immune system during severe trauma (3), G is a precursor of nucleotides (4) . Despite these properties, revealed by in vitro studies and animal experiments, the effect of G in critical illness and in surgical patients is not well understood. The clinical benefits of enterally and parenterally administered G supplements are controversial (5) . For instance, enteral G supplements reduced infectious morbidity in trauma patients during a randomized clinical trial (6) but did not change the clinical end points in three studies of preterm infants (7), although infectious morbidity was decreased in very low birth weight neonates (8) . Muscle and plasma G concentrations are depleted in severe burn injury (9) , yet no clinical data have been reported on the effect of G supplementation on the clinical course and immune system of such patients. The main objective of this randomized clinical trial was to measure the impact of enteral G supplementation on infectious morbidity and length of care in adult patients with severe burns. Another objective was to compare phagocytosis by blood polymorphonuclear cells (PMN) with and without G supplementation since it has been shown that G in vitro increases the phagocytosis capacity of PMN in burned children (10) .
METHODS

Study Design
In this prospective randomized clinical trial with a double-blind design, patients admitted to our burn center were assigned to one of two groups according to a randomization table with stratification of burn severity: 20 -40%, 40 -60%, and 60 -80% of total burn surface area. Randomization was concealed so that the study investigators were not aware in advance to which group the patients would be assigned. The individual in charge of patient allocation was reached by phone when a patient was admitted during weekends. This individual who prepared the G or isonitrogenous control mixture (C) provided to the nurses was not involved in data collection. The nursing staff and the surgical and medical caregivers were not aware of the patients' group assignment. Informed consent was obtained from the patients or their relatives. The study lasted from admission to the complete healing of burn wounds and donor sites. The protocol was approved by the Clinical Research Ethics Committee of our institution.
Patients and Patient Care
The study population consisted of 45 adult patients admitted to our burn center between July 1998 and May 2001, within 24 hrs of thermal injury exceeding 20% of total burn surface area, not including first-degree burns. The exclusion criteria were age Ͼ65 yrs; total burn surface area Ͼ80%; pregnancy; chronic respiratory, cardiac, or renal deficiency; and cancer. A severity index was calculated for each patient as follows: total burn surface area (ϩ20% if inhalation injury) ϩ age (10) The Parkland formula (12) was used for fluid resuscitation with Ringer's lactate solution and targeted to achieve 40 mL/hr urinary output. Debridement and grafting were performed within 7 days postadmission. With the exception of the hands, burn wounds were left without dressing and without antiseptic ointment until grafting. Inhalation injury was assessed by bronchoscopy on admission. Pain was managed with morphine intravenously: Continuous infusion was accompanied by bolus administration during the therapeutic procedures. Most patients were intubated preventively and ventilated artificially.
Nutritional Support
Enteral nutrition in all patients was started within 24 hrs of admission through a nasoenteral tube (Entube, Duluth, GA) inserted under endoscopic guidance into the third portion of the duodenum. The initial rate of 30 mL/hr was increased every 12 hrs up to 120 mL/hrs, depending on patient tolerance. All patients were given Sandosource (Novartis, Minneapolis, MN). In this formula, 15% of energy is derived from fat, 20% from proteins, and 65% from carbohydrates. There are no added immunonutrients. A gastric tube was inserted to ensure continuous emptying of gastric secretions. When necessary, parenteral nutrition was started to meet the nutritional requirements of the patients as soon as possible. This parenteral nutrition commenced within 48 hrs of admission. Criteria for starting parenteral nutrition were as follows: failure to reach the goal for caloric intake 24 hrs postadmission or calculated energy requirements at entry Ͼ2900 kcal/day. Dextrose solution 20% with amino acids 6.5% (Vamine, Clintec, Mississauga, Ontario, Canada) was delivered, as was Intralipid 20%. Vamine solution does not contain glutamine. Energy requirements were calculated with the Curreri formula (13) and adjusted for the measurement of energy expenditure by indirect calorimetry (Deltatrac Monitor, Sensormedics, Anaheim, CA) twice a week, as described previously (14) . The energy derived from fatty acids was 15% of total delivered energy. Protein delivery was set at 25% of total energy with a maximum of 2.5 g/kg of body weight. Zinc (10 mg), folic acid (2.5 mg), and vitamin C (500 mg) were added to the daily dextrose-amino acid mixture. Vitamins and trace elements were added as follows: Multidouze (SABEX, Boucherville, Quebec, Canada) 10 mL/L, and Microplus 6 (SABEX) 1 mL/L.
Upon insertion of the feeding tube, the patients received either 4.3 g of G (Cambridge Neutraceutical, Boston, MA) every 4 hrs, for a total of 26 g/day, or an isonitrogenous mixture of aspartic acid, asparagine, and glycine. Amino acids and G were administered in 50 mL of sterile water through the feeding tube. G or the amino acid mixture was continued even when enteral nutrition was interrupted for surgical procedures. G or amino acids were given until the end of the study, which was determined as the time to complete wound healing.
Sample Collection and Biochemistry
Urine Analyses. Twenty-four-hour urine was collected throughout the study and weighed to the nearest gram, and its volume was determined by weight and density. Total nitrogen (Antek, Houston, TX) and cortisol (Immunocorp, Diagnostic Systems Laboratories, Webster, TX) were measured in all samples.
Blood Analyses. Blood was sampled every 3 days between 7 and 9 am, day 1 being the morning after admission. Blood was collected before the administration of amino acids. Each sample underwent routine biochemistry, blood cell count, and the quantification of immature neutrophils (from microscopic examination if Ͼ0.05% of white blood cells appeared abnormal during automatic counting). Cholesterol, triglycerides, and liver enzymes were measured twice a week. Serum G was quantitated by reverse-phase (ODS-hypersil 2.1 ϫ 250 mm) high-performance liquid chromatography with precolumn derivatization (ophtaldehyde/mercaptopropionic acid) (15) .
Neutrophil Functions. Phagocytosis was measured by fluorescent Staphylococcus aureus analysis and flow cytometry (16) . Cell concentration was adjusted to 5 ϫ 10 6 PMN/ mL. Fluorescent bacteria were opsonized with normal serum added to the cell suspension to obtain a ratio of 100 bacteria per leukocyte and incubated at 37°C. At different intervals (0, 1, 3, and 18 hrs), cell phagocytic activity was analyzed by flow cytometry. To measure specific phagocytosis, adsorbed bacteria on cell surfaces were quenched with trypan blue stain. Forward and side scatter was used to gate PMN and to quantitate percent phagocytosis. The results were expressed in absolute number of PMN that ingested bacteria. Phagocytosis was confirmed by fluorescence microscopy.
Plasma interleukin (IL)-6 and IL-2R␣ concentrations were measured by enzyme-linked immunosorbent assay, as described previously (17) . The lower detection limits of the assay are 16 and 20 pg/mL for IL-2R␣ and IL-6, respectively.
Clinical Status. Mechanically ventilated patients were treated in the intensive care unit (ICU) with continuous monitoring of blood pressure, heart rate, central temperature, and electrocardiogram. Insulin was administered intravenously if blood glucose exceeded 10 mmol/L. The goal was to maintain blood glucose below this value. A lung injury score was computed twice a week as follows (18) Chest roentgenograms: no alveolar consolidation, 0; alveolar consolidation in one quadrant, 1; two quadrants, 2; three quadrants, 3; four quadrants, 4; possible lung injury score ranged from 0 to 12.
A chest radiologist unaware of patient group assignment examined the chest roentgenograms at once. Blood was cultured in duplicate when body temperature was Ͼ38.5°C or Ͻ36.5°C. Samples were obtained from a central catheter in most instances. Wound infection was monitored in culture by swab sampling of the wounds. Length of care was the time from admission to the complete healing of grafted and ungrafted wounds, including donor sites, as determined by the surgical team. This variable was studied in survivors only since nonsurvivors died before their wounds healed.
Statistical Analyses
Variables were analyzed by two-way analysis of variance for repeated measurements. Frequency distributions were analyzed by chisquare tests with corrections for small samples or with Fisher's exact test when appropriate. The hypotheses tested were that patients in the G group would have fewer positive blood cultures (PBCs) and respiratory infections than the C group. The mortality data were analyzed per intention to treat, including all 45 randomized patients, and per protocol, excluding three patients who died within 72 hrs of admission and one who could not be fed enterally and did not receive G.
RESULTS
Of the 45 randomized patients, three died within 72 hrs and one could not receive enteral nutrition and amino acid supplements for the first 10 days. These patients were excluded from the analyses, with the exception of analysis of mortality rate, in which they were included in the intention-to-treat analysis.
The clinical characteristics of the 41 patients who participated in the study are shown in Table 1 . There was no difference between groups for age, weight, male/ female ratio, severity of burns in the three predetermined categories, number of patients with inhalation injury, and the presence of a comorbid condition. The severity index was similar between groups: 97 Ϯ 20 and 87 Ϯ 27 for C and G, respectively. The number of patients with a severity index Ͼ100 was nine and seven in groups C and G, respectively.
Nutritional data on energy and protein intake, resting energy expenditure, nitrogen balance, insulin received, urinary cortisol excretion, and blood glucose are presented in Table 2 . There were no differences in these variables between groups. The proportion of energy given parenterally was similar between groups: 39 Ϯ 12% vs. 42 Ϯ 14% for C and G, respectively. No patient received glucocorticoids during the study.
Clinical outcomes other than infectious status are listed in Table 3 . Table 4 . The incidence of PBC was three times higher in C vs. G: 4.3 vs. 1.2 days/patient (p Ͻ .05). In addition, the number of patients with PBC for Ͼ2 days of study time was higher in C: seven vs. zero in G (p Ͻ .01). From the total blood cultures made in each group, 7.5% were positive in the G group and 19% in group C (p Ͻ .05). The type of bacteria found in blood cultures was not different between groups: three Gram-negative patients in G vs. seven in C. The number of patients positive for Pseudomonas aeruginosa was zero and six for G and C, respectively (p Ͻ .05). Among the patients who died, four had PBCs, all for P. aeruginosa. All other variables were not statistically different between groups. No differences in biochemical variables or blood cell count were observed (data not shown). The data on blood PMN phagocytosis, serum IL-6 and IL2-R␣ concentrations, and serum M/F, males/females; TBSA, total burn surface area; FT, full thickness; PT, partial thickness. Co-morbid conditions included diabetes, obesity, hypertension, mental disease, and drug addiction. Values are absolute numbers or mean Ϯ SD. glutamine are shown in Table 5 . There was no difference between groups for these variables.
DISCUSSION
The main findings of this study are a reduction of blood infections and a decrease in mortality rate in the G-supplemented group. The two groups of randomized patients were similar with respect to age, gender distribution, severity of injury, and associated inhalation injury. All patients had full thickness burns. The reduction of bacteremia observed in our study is in agreement with the findings of Houdijk et al. (6) in trauma patients given enteral G. In our study, G-supplemented patients had more than three times fewer PBCs than C patients, a decrease similar to the results in trauma patients. The mechanism of this phenomenon is unclear.
Animal studies suggest that G exerts a protective effect on gut mucosa and prevents bacterial and endotoxin translocation from the intestinal lumen to the bloodstream (19) . It is also a critical nutrient for the proliferation and function of immune cells in vitro, and enteral G supplements could be hypothesized to improve immune functions in vivo. Our data could support the translocation theory but without definitive arguments: The number of patients with Gramnegative bacteremias was not different between groups, but the average duration of this type of infection was longer in group C and came close to statistical significance. This contrasts with the results in trauma patients, where G supplementation suppressed Gram-negative bacteremia whereas in group C more than half of the PBCs were Gram-negative. Our results differ as well from a recently published study on burn patients who received G parenterally (20) . In that investigation, one patient of 12 had Gram-negative bacteremia in the G group compared with six of 14 in group C, but the overall incidence of bacteremia was not different between groups. Together with our results, these data are not sufficient to support the "gut barrier" hypothesis for the effect of G in burn patients, and a larger number of observations are needed here. It should also be mentioned that bacterial translocation remains a controversial mechanism of nosocomial infection in humans (21) .
Several findings in our study support an effect of G within the gut: First, there was no significant increase in plasma G concentrations between groups, and it is difficult to hypothesize that the immune system outside the gut would have been affected. This lack of difference in plasma G has been observed in other trials and is attributed to the fact that most of the G administered is taken up by the gut. Second, there was no difference in the incidence of wound infection and in the severity of respiratory disease between the groups. This argues against a systemic G effect. Third, the phagocytic capacity of blood neutrophils was not altered by G administration, which does not concur with an effect of G on the immune system outside the gut. In addition, we did not observe a difference in the inflammatory response, since plasma IL-6 and IL-2R␣ concentrations were similar in the 2 groups. We have found both these peptides to be related to infectious status in burn injury (17) . Finally, nitrogen balance and cortisol excretion were not different between groups. This is in agreement with the results in trauma patients, in whom enteral G supplements did not modulate hormonal and metabolic factors (22) . An effect of G other than the protection of gut barrier integrity is also possible. As a precursor of glutathione, G has major antioxidant properties particularly on gut mucosa (19) , and this may be protective of immune functions in the gut. Finally, an effect of G on immune defense of our patients cannot be ruled out because T-lymphocyte functions, which are inhibited by burn injury, were not measured. The lack of difference in plasma G is also difficult to interpret because G was given as boluses, and tran- Groups: sient increases in plasma G concentration might have occurred in group G. The absence of blood infection with P. aeruginosa in G-supplemented patients suggests that G may prevent the translocation of this particular bacterium across the gut mucosa. Whether the effect is related to the action of G on the gut itself or on the behavior of the bacterium remains to be determined. A hypothesis can be generated from our data on P. aeruginosa: This bacterium may be sensitive to the amount of G in its environment; a lack of G may trigger both proliferation and crossing of the epithelial barrier. Together with weakening of the gut immune system, related at least in part to G deficiency, these phenomena may explain P. aeruginosa translocation.
Blood infection with P. aeruginosa may account for, at least in part, the results on mortality rate in our study, since four of eight patients in group C who died had septicemia with P. aeruginosa. This bacterium is a major cause of infectious morbidity and mortality in burn and ICU patients (23, 24) .
The second finding of our study was the effect of G administration on mortality rate. No patient who received G died after 72 hrs of admission. In group C, the observed mortality rate was similar to that in our burn center for this category of patient (25) . As the study was blinded to all caregivers, the outcome was unlikely to have been biased by the quality of care received by G-supplemented patients. The severity of injuries and the incidence of inhalation injury were identical in both groups, and the results cannot be explained by a reduced risk of dying at entry in the G group. We conclude that the decreased mortality in G is related to its administration. This finding should be confirmed in a multiple-center trial since our study was not powered to address the issue of mortality, and because such a study would take into account possible variations between burn centers. Such an effect of G would be the first intervention with a single nutrient that improves survival in burn patients. The importance of this finding is also related to the fact that in developed countries, survival in severely burned adults has not improved in the past 20 yrs (26) . The mechanism of the G effect on mortality rate in our patients can only be speculated upon. Indeed, the reduction of blood infections is likely to be related to the effect on survival. In patients who received placebo, blood infection was more frequent and more prolonged. The number of patients was not sufficient, however, for a meaningful comparison between survivors and nonsurvivors with regard to blood infections.
Whether the effect of enteral G administration on survival is specific to burn patients or could be observed in other ICU patients remains to be investigated. In a study of 50 ICU patients, Jones et al. (27) did not find an effect on mortality rate within the group that received an enteral solution enriched with G. This difference from our results may be related to patient condition, to the amount of G given (average supplementation of 10 g/day vs. 26 g/day in our study), or to the mode of administration (continuous vs. bolus). In a recent meta-analysis, Novak et al. (28) analyzed 14 randomized trials comparing the use of G supplementation in surgical and critically ill patients. From subgroup analyses, they concluded that a trend could be identified favoring the prescription of G parenterally, at a dose Ͼ0.23 g·kg Ϫ1 ·day Ϫ1 . This conclusion is based on the observation that none of the three trials with enteral G supplements showed an effect on mortality rate or length of stay, whereas parenteral administration was associated with a significant reduction of both mortality rate and length of stay. In contrast with this conclusion, our study demonstrates decreased mortality rate with enteral G administration but no effect on length of care. The discrepancy may come from the patient population as well as the amount and route of G administration. Indeed, burn patients may benefit the most from improved gut barrier function, including the competence of the gut immune system, because mortality rate is associated with systemic infection in this population. It is also noteworthy that a reduction in blood infection similar to our observation was seen by Houdijk (22) in trauma patients who received G as boluses with an amount close to what was given to our patients. From these findings, it can be concluded that the route and regimen of G administration should be investigated further. Concomitant administration of G by both the enteral and parenteral routes may be warranted in some patients.
CONCLUSION
The results of this prospective randomized clinical trial show that enteral G reduces blood culture positivity, particularly with P. aeruginosa, in adults with severe burns and may be a life-saving intervention.
